Clinical Edge Journal Scan

TNBC: Lower recurrence risk with breast-conserving surgery compared with mastectomy


 

Key clinical point: In patients with triple-negative breast cancer (TNBC), the risk for locoregional recurrence and distant metastasis is lower when treated with breast-conserving surgery (BCS) vs. mastectomy.

Major finding: BCS vs. mastectomy was associated with lower risk for locoregional recurrence (unadjusted pooled odds ratio, 0.64; P = .002). The risk for distant metastasis was also significantly lower with BCS vs. mastectomy (unadjusted pooled odds ratio, 0.70; P = .02).

Study details : A meta-analysis of 14 studies including 19,819 patients with TNBC who underwent either BCS or mastectomy.

Disclosures: This meta-analysis was supported by investigator grants from the National Health and Medical Research Council and the National Breast Cancer Foundation. The authors declared no conflicts of interest.

Source: Fancellu A. Br J Surg. 2021 May 31. doi: 10.1093/bjs/znab145 .

Recommended Reading

CONCERT: Better QoL but not survival with cabazitaxel in metastatic HER2– breast cancer
MDedge Hematology and Oncology
Pilot study: Hybrid laser found effective for treating genitourinary syndrome of menopause
MDedge Hematology and Oncology
Promising HER2+/HR– breast cancer survival with de-escalated therapy
MDedge Hematology and Oncology
Freezing breast cancer to death avoids surgery: Why not further along?
MDedge Hematology and Oncology
DCIS: Biosignature helps guide postlumpectomy decisions
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: Breast Cancer July 2021
MDedge Hematology and Oncology
Adjuvant olaparib yields survival benefit in HER2-negative BRCA1/2 breast cancer
MDedge Hematology and Oncology
Residual TNBC: Platinum therapy does not improve outcomes
MDedge Hematology and Oncology
Adding ribociclib extends survival in HR-positive, HER-negative breast cancer
MDedge Hematology and Oncology
HR-positive breast cancer: Aromatase inhibitors-based treatment yields survival benefit
MDedge Hematology and Oncology